We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Multiple Sclerosis Drug Under Review by FDA, EMA
Read MoreHide Full Article
Roche Holding (RHHBY - Free Report) announced that the FDA has accepted its Biologics License Application (BLA) for Ocrevus (ocrelizumab) for review as the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
The BLA was also granted Priority Review Designation with a targeted action date of Dec 28, 2016.
Additionally, the EMA has validated Roche’s Marketing Authorization Application (MAA) for Ocrevus.
We note that Priority Review Designation is granted to medicines that the FDA believes to have the potential for significant improvements in safety and effectiveness of a treatment of a serious disease.
Earlier in 2016, the FDA had granted Breakthrough Therapy designation to Ocrevus for the treatment of PPMS.
We note that Roche is evaluating Ocrevus in a phase III development program – OPERA I, OPERA II and ORATORIO. While OPERA I and OPERA II are identical phase III, randomized, global multi-center studies that are evaluating the efficacy and safety of Ocrevus (600 mg administered by intravenous infusion every six months) versus interferon beta-1a (44 mcg administered by subcutaneous injection three times per week) for the treatment of relapsing forms of MS (relapsing-remitting MS and secondary progressive MS with relapses).
Meanwhile, the randomized phase III study, ORATORIO, is evaluating the efficacy and safety of Ocrevus (600 mg administered by intravenous infusion every six months) as compared to placebo in patients with PPMS.
We are impressed by the company's efforts to grow its portfolio beyond oncology and foray into new avenues such as MS and asthma. Roche currently has more than a dozen pipeline candidates for diseases that include MS, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease, Down syndrome and autism.
The company currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Pfizer, Inc. (PFE - Free Report) , Bristol-Myers Squibb Co. (BMY - Free Report) and Johnson & Johnson (JNJ - Free Report) . While Pfizer and Bristol-Myers sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Roche's Multiple Sclerosis Drug Under Review by FDA, EMA
Roche Holding (RHHBY - Free Report) announced that the FDA has accepted its Biologics License Application (BLA) for Ocrevus (ocrelizumab) for review as the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
The BLA was also granted Priority Review Designation with a targeted action date of Dec 28, 2016.
Additionally, the EMA has validated Roche’s Marketing Authorization Application (MAA) for Ocrevus.
We note that Priority Review Designation is granted to medicines that the FDA believes to have the potential for significant improvements in safety and effectiveness of a treatment of a serious disease.
Earlier in 2016, the FDA had granted Breakthrough Therapy designation to Ocrevus for the treatment of PPMS.
We note that Roche is evaluating Ocrevus in a phase III development program – OPERA I, OPERA II and ORATORIO. While OPERA I and OPERA II are identical phase III, randomized, global multi-center studies that are evaluating the efficacy and safety of Ocrevus (600 mg administered by intravenous infusion every six months) versus interferon beta-1a (44 mcg administered by subcutaneous injection three times per week) for the treatment of relapsing forms of MS (relapsing-remitting MS and secondary progressive MS with relapses).
Meanwhile, the randomized phase III study, ORATORIO, is evaluating the efficacy and safety of Ocrevus (600 mg administered by intravenous infusion every six months) as compared to placebo in patients with PPMS.
ROCHE HLDG LTD Price and Consensus
ROCHE HLDG LTD Price and Consensus | ROCHE HLDG LTD Quote
We are impressed by the company's efforts to grow its portfolio beyond oncology and foray into new avenues such as MS and asthma. Roche currently has more than a dozen pipeline candidates for diseases that include MS, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease, Down syndrome and autism.
The company currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Pfizer, Inc. (PFE - Free Report) , Bristol-Myers Squibb Co. (BMY - Free Report) and Johnson & Johnson (JNJ - Free Report) . While Pfizer and Bristol-Myers sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>